Post Market Registry Study of the Philips QuickClear Mechanical Thrombectomy System

Running, not enrolling

Conditions studied: Acute Deep Venous Thrombosis of Ileofemoral Vein

In brief

A post-market study of the QuickClear Mechanical Thrombectomy system used for the removal of acute Deep Vein Thrombosis (DVT) from the deep veins of legs in the setting of an office interventional suite.

Key facts

Study ID

NCT05928221

Run by

Paul J. Gagne

People needed

50

Starts

2023-06-14

Expected to finish

2026-07-01

Last updated by the study team

2026-02-06

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or Non-Pregnant Female, age 18 to 89.
• For females of reproductive potential: negative pregnancy test ≤ 7 days before the procedure, use of highly effective contraception (abstinence is acceptable) for 12 months after the study treatment.
• Onset of acute DVT symptoms of 14 days or less in the target limb.
• Ability to take oral medication and be willing to adhere to the prescribed anti- coagulant regiment.
• Occlusive DVT (confirmed by either venous duplex ultrasound or CT venogram) spanning at least one of the following:
• the iliac and/or common femoral vein. Extension into the femoral vein and/or profunda vein is allowed. OR
• the entire popliteal vein (above and below knee). Extension into the femoral vein and/or tibial veins is allowed.
• People who have scheduled or will be scheduled for treatment with the QuickClear Mechanical Thrombectomy system
• Symptomatic DVT defined as meeting at least one of the following clinical indicators:
• rVCSS Pain Score ≥2
• New edema of calf or thigh (CEAP ≥3)

You may not qualify if…

• Non-ambulatory status prior to DVT occurrence.
• Inability to lie in supine or prone under local anesthesia with moderate sedation for procedure.
• In the contralateral (non-study) leg: symptomatic DVT that, in the operating physician's opinion, will require treatment in the following 30 days.
• Critical limb ischemia with ulcer, gangrene, or rest pain (i.e., above symptoms or findings and ankle-brachial index <0.5, absolute ankle pressure <50 mm Hg or absolute toe pressure <30 mmHg).
• Pulmonary embolism (PE) defined as either massive (systolic blood pressure < 90 mm Hg and/or patient on IV vasoactive medication to support blood pressure), or intermediate high-risk PE, as defined by the European Society Guideline on management of PE. Low-risk PE and/or intermediate low-risk PE can be enrolled.
• Inability to tolerate contemporary venous intervention procedure due to severe dyspnea or acute systemic illness.
• Allergy, hypersensitivity, or thrombocytopenia from heparin, iodinated contrast, except for mild-moderate contrast allergies for which steroid pre-medication can be used.
• History of, or active heparin-induced thrombocytopenia (HIT).
• Hemoglobin ≤9.0 mg/dl, INR>1.6 before starting anticoagulation, or platelets < 100,000/ml. Moderate renal impairment in diabetic patients (eGFR <60 ml/min) or severe renal impairment in non-diabetic patients (eGFR< 30 ml/min).
• Active bleeding, recent (< 3 mo) GI bleeding, severe liver dysfunction, bleeding diathesis.
• Recent (< 3 mo) internal eye surgery or hemorrhagic retinopathy; recent (<10 days) major surgery, cataract surgery, trauma, cardiopulmonary resuscitation, or other invasive procedure; or obstetrical delivery < 72 hours prior to procedure.
• History of hemorrhagic stroke or intracranial/intraspinal bleed, tumor, vascular malformation, aneurysm.
• Active cancer with a life expectancy of < 1 year.
• Severe hypertension on repeated readings (systolic blood pressure > 180 mm Hg or diastolic blood pressure >105 mmHg). This can be treated, and blood pressure must be stable before venous access is obtained (systolic blood pressure < 150 mmHg, diastolic blood pressure < 100 mm Hg).
• Pregnant or breastfeeding or plans to become pregnant in the next 12 months.
• Thrombus of the inferior vena cava (IVC) extending at least one centimeter above the common iliac vein confluence.
• Inability to obtain venous access.
• Contraindication to Enoxaparin (e.g., Severe chronic kidney injury, allergic reaction, HIT)

Where it is running

• Vascular Care Connecticut — Darien, Connecticut, United States
• The Vascular Care Group — Hyannis, Massachusetts, United States
• The Vascular Care Group — Leominster, Massachusetts, United States
• The Vascular Care Group — Plymouth, Massachusetts, United States
• The Vascular Care Group — Wellesley, Massachusetts, United States
• The Vascular Care Group — Worcester, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.